# Cardiovascular Inflammation Reduction Trial

Study · id `cardio:ct-nct01594333` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01594333](<https://clinicaltrials.gov/study/NCT01594333>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01594333

Browse, organ or system: Heart; Brain; Metabolism  
Browse, condition area: Coronary and vascular disease; Stroke; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4786 participants.

## Technical summary

Registry record NCT01594333. Randomized; triple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2019-04-15 (actual). Results posted on 2020-07-24.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4786 participants (enrolled count; ClinicalTrials.gov record NCT01594333, source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)
- Start date: 2013-04 (registry gives no type) (ClinicalTrials.gov record NCT01594333, source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)
- Primary completion: 2019-04-15 (actual) (ClinicalTrials.gov record NCT01594333, source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)
- Completion: 2019-10-30 (actual) (ClinicalTrials.gov record NCT01594333, source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)
- Results first posted: 2020-07-24 (ClinicalTrials.gov record NCT01594333, source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)
- Countries: United States; Canada; Puerto Rico (ClinicalTrials.gov record NCT01594333, source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01594333-2020-07-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular Inflammation Reduction Trial
- Acronym: CIRT
- Condition: Cardiovascular Disease
- Intervention (Drug): Methotrexate
- Intervention (Drug): Placebo
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Adverse Effects of Low-Dose Methotrexate: A Randomized Trial (`cardio:pubmed-32066146`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial (`cardio:pubmed-32221587`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial (`cardio:pubmed-32741143`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial (`cardio:pubmed-34144603`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial (`cardio:pubmed-34551998`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease (`cardio:pubmed-35606100`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate (`cardio:pubmed-35671649`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk (`cardio:pubmed-39657237`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2aa8bc2ccd1f3b33f31779e5fef398613af5f213e26fbefaf07e1d5ec6862af0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
